Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-? (FR?) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting ...

The study design defined HER2 positive as immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridization (ISH)+. The trial enrolled 494 patients across Asia, Europe, and South America. Patients aged 18 ...